SlateStone Wealth’s Matinas BioPharma MTNB Stock Holding History

SlateStone Wealth’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200	Closed	-$1K	–	245
2023 Q3	$1K	Hold	200	–	–	﹤0.01%	227
2023 Q2	$4K	Hold	200	–	–	﹤0.01%	212
2023 Q1	$5K	Hold	200	–	–	﹤0.01%	206
2022 Q4	$5K	Hold	200	–	–	﹤0.01%	195
2022 Q3	$6K	Buy	+200	New	+$7.86K	﹤0.01%	183

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MSFS

Main Street Financial Solutions Newtown, Pennsylvania $1.34B AUM 19.49% 1-Year Est. Return

SlateStone Wealth's MTNB Position: Q4 2023 in Review

SlateStone Wealth sold out of Matinas BioPharma (MTNB) in Q4 2023, closing a stake of 200 shares — an estimated $1K sold.

SlateStone Wealth first reported a position in MTNB in Q3 2022 and held it in 5 quarters. The position peaked at $6K in Q3 2022. 51 funds tracked by Wall St. Rank hold MTNB as of Q4 2023.

SlateStone Wealth reported no remaining Matinas BioPharma position as of Q4 2023 after selling out during the quarter.
SlateStone Wealth sold 200 Matinas BioPharma shares in Q4 2023, an estimated $1K.
SlateStone Wealth first reported a position in Matinas BioPharma in Q3 2022 and held it in 5 quarters.
SlateStone Wealth's Matinas BioPharma position peaked at $6K in Q3 2022.
51 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2023.

Based on SlateStone Wealth's 13F filing for Q4 2023, filed 1 Feb 2024.